Relief Therapeutics Announces Filing of IND for Phase 2/3 Clinical Trial of Inhaled RLF-100 Targeting Early COVID-19 Lung Injury
May 11, 2020 02:00 ET
|
Relief Therapeutics
Study to enroll 144 patients with COVID-19-associated non-acute lung injury in an attempt to decrease progression to Acute Respiratory Distress Syndrome and need for ICU careRLF-100, a patented...